Morgan Stanley 2013 R&D Seminar: Reigniting Pharma

  • 695 views
Uploaded on

Mikael Dolsten, M.D., Ph.D. …

Mikael Dolsten, M.D., Ph.D.
President, Worldwide R&D

  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Be the first to comment
    Be the first to like this
No Downloads

Views

Total Views
695
On Slideshare
0
From Embeds
0
Number of Embeds
1

Actions

Shares
Downloads
10
Comments
0
Likes
0

Embeds 0

No embeds

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
    No notes for slide

Transcript

  • 1. Pfizer R&D Overview Mikael Dolsten, M.D., Ph.D. President, Worldwide R&D May 10, 2013
  • 2. 2 Forward-Looking Statements and Non-GAAP Financial Information • Our discussions during this meeting will include forward-looking statements. Actual results could differ materially from those projected in the forward- looking statements. The factors that could cause actual results to differ are discussed in Pfizer’s 2012 Annual Report on Form 10-K/A and in our reports on Form 10-Q and Form 8-K. • Also, the discussions during this meeting will include certain financial measures that were not prepared in accordance with U.S. generally accepted accounting principles. Reconciliations of those non-U.S. GAAP financial measures to the most directly comparable U.S. GAAP financial measures can be found in Pfizer’s Current Report on Form 8-K dated April 30, 2013. • These reports are available on our website at www.pfizer.com in the "Investors - SEC Filings" section.
  • 3. Continue to Execute on a Multi-year R&D Turnaround 3 2010 Drive the Transformation Shift to more value on lower cost base • Execute on recent product launches • Embed Precision Medicine • Continue to lead in novel collaborations • Increase portfolio quality, value, IRR • Improve clinical trial quality & consistency • Focus on culture & talent Deliver a Sustainable Flow of Innovative Therapies R&D delivers clear ROI • Increased focus and rigor in the portfolio • Integrated science & business • Moved Research to bioinnovation hubs • Advanced next-generation drug design • Launched CTI • Reduced R&D costs Lay the Foundation Interrogate and change the Pfizer R&D model • Important new product launches every year • Strong productivity and return for patients and shareholders • Emerge as nodal player in the health ecosystem
  • 4. Recent Approvals Strong Pipeline Momentum 4 Phase 2 Phase 3 In Reg. 25 25 18 6 Phase 1 Total 74 Discovery Projects Pipeline Snapshot as of May 9, 2013
  • 5. Highlights from the Mid-to-Late Stage Portfolio 5 Key Next Wave Programs Xeljanz Crohn’s, Ankylosing Spondylitis IL6, Anti-MAdCAM, Oral P38 Chronic Inflammatory Diseases SMO, PI3K mTOR Solid Tumor and Blood Cancers (SMO) S. aureus and C. difficile Vaccines Prophylaxis of key Hospital-acquired Infections Anti-PCSK9, SGLT-2 Cardiovascular and Type 2 Diabetes PDE5 Inhibitor and CCR 2/5 Inhibitor Chronic Kidney Disease GMI-1070* Vaso-occlusive Crisis, Sickle Cell Disease Biosimilar trastuzumab & rituximab Key Late Stage Programs Xeljanz Phase 3 studies in Ulcerative Colitis & Psoriasis Eliquis VTE Treatment & Prevention Palbociclib Advanced ER+HER2- Breast Cancer Inotuzumab Ozogamicin Aggressive Non-Hodgkin's Lymphoma and Acute Lymphoblastic Leukemia Dacomitinib Non-Small Cell Lung Cancer Meningococcal B Adolescent Vaccine Prevention of Meningococcal Infection *Pfizer has exclusive license from GlycoMimetics
  • 6. Q&A